The role of laboratory test biomarkers in diagnosis, risk assessment, and monitoring of COVID-19 patients

Government officials, healthcare providers, and scientists continue their efforts to identify and find ways of treatment regarding the coronavirus infection (CoV), also known as Severe acute respiratory syndrome coronavirus 2. This is due to the fact that the COVID-19 infection is ongoing and there is a possibility of new infections or new waves of disease. In addition to this possibility, there is also the continuity of the COVID-19 infection (SARS-CoV-2). Researchers have a pressing need for adequate biomarkers that are associated with the progression of SARS-CoV-2 in order to stratify patients who are at high risk. Because the disease can spread so rapidly, patients need to be classified into risk groups as soon as possible after their diagnosis in order to make the most efficient use of available resources. In addition, new markers are required in order to identify patients who have a rapid progression of their disease, which can lead to death or a serious infection. It is essential to gain a comprehension of the viral pathogenetic mechanisms, as well as the cellular and organ damage, prior to the discovery of novel biomarkers. The clinical management, screening, and prevention of serious complications could all be improved with the use of reliable biomarkers. To effectively manage the COVID-19 pandemic, future prevention, prompt diagnosis, superior treatment, and precise detection are not only extremely important but also have the potential to assist in reducing the spread of the virus. According to the conventional medical consensus, biomarkers play a very important role in the prompt detection of the etiology, treatment, diagnosis, and prognosis of a disease. This work discusses emerging and known biomarkers for detecting SARS-CoV-2 diagnostics, prognosis, and treatment in order to assist the numerous innovations and investigations that are currently taking place